SEATTLE--(BUSINESS WIRE)--Jan. 5, 2006--Pacific Biometrics, Inc. (OTCBB: PBME, “PBI”) has been awarded a series of contracts with a top multinational pharmaceutical company (the “Sponsor”) to provide essential clinical data for a pivotal, global Phase III cardiovascular program. These contracts are part of a series of previously announced contracts related to an innovative approach for the prevention and treatment of dyslipidemia, atherosclerosis, and coronary heart disease.
